Supernus Pharmaceuticals (SUPN) AI Stock Analysis

• Market Cap: $2.36B
• Dividend Yield: N/A
• Average Volume (3M): 923.59K
• Price to Earnings (P/E): 36.9
• Beta (1Y): 0.67
• Revenue Growth: 5.55%
• EPS Growth: 1145.24%
• Country: US
• Employees: 674
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.91
• Shares Outstanding: 56,073,090
• 10 Day Avg. Volume: 1,406,786
• 30 Day Avg. Volume: 923,589
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.55
• Enterprise Value/Revenue: 1.95
• Enterprise Value/Gross Profit: 2.36
• Enterprise Value/Ebitda: 7.80
• 1Y Price Target: $42.80
• Price Target Upside: 0.26% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 76 Outperform
• Price Target: $48.00 ▲(12.44% Upside)

Supernus Pharmaceuticals demonstrates strong financial health and technical momentum, supported by strategic acquisitions. However, high valuation and patent challenges pose risks. The company's robust cash flow and operational efficiency are key strengths, but attention to revenue growth and cost management is crucial for sustaining long-term performance.

Positive Factors

Earnings

Qelbree achieved $77.6MM in Q2 sales, exceeding consensus and showing strong growth.

Market Growth

Analyst expects Qelbree to steadily grow, focusing on the adult launch with increasing adoption in the segment.

Patent Extension

Qelbree's '338 patent has been extended by 2 years to 2035, which buys time for management to introduce more pipeline assets.

Negative Factors

Clinical Trial Results

Disappointing Phase 2b data from SPN-820 in treatment-resistant patients led to a downgrade of the stock rating.

Stock Rating

Downgrading SUPN to Neutral following disappointing Phase 2b data from SPN-820.

Supernus Pharmaceuticals Business Overview & Revenue Model

Company Description

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative products for the treatment of central nervous system (CNS) diseases. The company primarily operates in the pharmaceutical sector, specializing in therapies for epilepsy, depression, and attention deficit hyperactivity disorder (ADHD). Supernus's core products include several FDA-approved medications such as Oxtellar XR and Trokendi XR, which are designed to address the needs of patients suffering from these conditions.

How the Company Makes Money

Supernus Pharmaceuticals generates revenue primarily through the sale of its prescription medications. The company's key revenue streams include sales of its core products, particularly Oxtellar XR and Trokendi XR, which are marketed to healthcare providers and patients. Additionally, Supernus engages in strategic partnerships and collaborations with other pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on sales of co-developed products. The company's focus on expanding its product portfolio through research and development initiatives, along with potential new product launches, also contributes to its revenue generation. Supernus's earnings are further supported by its ability to navigate the complex regulatory environment for drug approvals, ensuring that its products reach the market effectively.

Supernus Pharmaceuticals Financial Statement Overview

Summary

Supernus Pharmaceuticals demonstrates a strong financial position with robust margins and a solid equity base. The company maintains low leverage, reducing financial risk while ensuring ample liquidity. Despite moderate revenue growth, stable cash flows and efficient cost management underscore its operational resilience. Opportunities exist to enhance shareholder returns through improved net income generation.

Income Statement

Supernus Pharmaceuticals demonstrated a solid gross profit margin of 79.5% in the TTM, indicating strong cost management. The net profit margin of 9.3% suggests reasonable profitability, despite a slight decline from the previous year. Revenue growth is relatively modest, reflecting stable but limited expansion opportunities. EBITDA margin is healthy at 25.0%, supporting operational efficiency.

Balance Sheet

The company exhibits a robust equity position with an equity ratio of 76.5% in the TTM, highlighting financial stability. The debt-to-equity ratio is low at 0.03, indicating minimal leverage and reduced financial risk. Return on equity is moderate at 6.0%, suggesting room for improvement in generating returns for shareholders.

Cash Flow

Operating cash flow remains strong with an operating cash flow to net income ratio of 2.65, indicating efficient cash generation relative to income. Free cash flow growth has been stable, supporting potential reinvestment or shareholder returns. However, the free cash flow to net income ratio of 2.64 suggests a balanced but not overly aggressive cash deployment strategy.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	665.13M	661.82M	607.52M	667.24M	579.77M	520.40M
Gross Profit	547.45M	583.91M	523.74M	580.02M	504.71M	467.94M
EBITDA	166.03M	178.28M	90.04M	153.44M	129.19M	212.40M
Net Income	64.50M	73.86M	1.32M	60.71M	53.42M	126.95M
Balance Sheet
Total Assets	1.38B	1.37B	1.28B	1.70B	1.69B	1.50B
Cash, Cash Equivalents and Short-Term Investments	522.60M	453.61M	254.87M	461.33M	339.68M	422.53M
Total Debt	31.77M	34.27M	41.53M	437.97M	420.55M	390.33M
Total Liabilities	318.50M	332.34M	356.16M	816.30M	873.30M	759.24M
Stockholders Equity	1.06B	1.04B	921.52M	886.20M	815.85M	744.86M
Cash Flow
Free Cash Flow	185.87M	171.23M	110.53M	116.41M	125.08M	134.95M
Operating Cash Flow	187.06M	171.95M	111.08M	116.83M	127.13M	138.40M
Investing Cash Flow	-82.94M	-189.87M	268.73M	-216.66M	-81.91M	-34.70M
Financing Cash Flow	-11.50M	12.19M	-397.88M	-10.48M	-130.42M	3.56M

Supernus Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 42.69
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SUPN, the sentiment is Positive. The current price of 42.69 is above the 20-day moving average (MA) of 37.27, above the 50-day MA of 34.39, and above the 200-day MA of 34.55, indicating a bullish trend. The MACD of 2.55 indicates Negative momentum. The RSI at 76.01 is Negative, neither overbought nor oversold. The STOCH value of 86.13 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SUPN.

Supernus Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUPN	76 Outperform	$2.36B	36.86	6.38%	―	5.55%	1145.24%
ANIP	68 Neutral	$1.95B	―	-2.82%	―	38.68%	-160.14%
AMPH	62 Neutral	$1.40B	11.31	18.32%	―	1.37%	-18.10%
AMRX	58 Neutral	$2.95B	1,476.56	106.97%	―	9.81%	―
DVAX	54 Neutral	$1.25B	64.45	-9.28%	―	26.66%	-419.55%
Sector *	51 Neutral	$7.46B	-0.16	-46.00%	2.25%	22.76%	-2.28%
EVO	47 Neutral	$1.35B	―	-16.34%	―	0.45%	-125.61%

Supernus Pharmaceuticals Corporate Events

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

On July 31, 2025, Supernus Pharmaceuticals completed its acquisition of Sage Therapeutics, enhancing its presence in neuropsychiatric conditions with the addition of ZURZUVAE, an FDA-approved treatment for postpartum depression. The acquisition, valued at approximately $561 million, is expected to diversify Supernus’ revenue base and accelerate growth, with projected cost synergies of up to $200 million annually. The merger was completed without a stockholder vote, and Sage now operates as a wholly owned subsidiary of Supernus.

The most recent analyst rating on (SUPN) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Supernus Pharmaceuticals stock, see the SUPN Stock Forecast page.

Supernus Pharmaceuticals Holds Annual Stockholders Meeting

On June 16, 2025, Supernus Pharmaceuticals held its annual stockholders meeting, where key decisions were made regarding the election of directors, executive compensation, and the appointment of KPMG LLP as the independent public accounting firm for 2025. These decisions are expected to influence the company’s governance and financial oversight, impacting its strategic direction and stakeholder confidence.

The most recent analyst rating on (SUPN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Supernus Pharmaceuticals stock, see the SUPN Stock Forecast page.

Supernus Pharmaceuticals to Acquire Sage Therapeutics

On June 13, 2025, Supernus Pharmaceuticals announced a definitive agreement to acquire Sage Therapeutics through a tender offer valued at approximately $795 million. This acquisition is expected to enhance Supernus’ neuropsychiatry product portfolio with the addition of ZURZUVAE, an FDA-approved treatment for postpartum depression, and is anticipated to be significantly accretive by 2026, with potential cost synergies of up to $200 million annually.

The most recent analyst rating on (SUPN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Supernus Pharmaceuticals stock, see the SUPN Stock Forecast page.

Supernus Pharmaceuticals Faces Patent Challenges for Qelbree

On May 22 and 23, 2025, Supernus Pharmaceuticals received Paragraph IV Notice Letters indicating that third parties filed Abbreviated New Drug Applications (ANDAs) for viloxazine hydrochloride capsules, challenging the patents of their product Qelbree. Supernus plans to enforce its intellectual property rights, which are protected by six U.S. patents expiring between 2029 and 2035, potentially impacting its market position and stakeholder interests.

The most recent analyst rating on (SUPN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Supernus Pharmaceuticals stock, see the SUPN Stock Forecast page.